Peptide receptor scintigraphy with [111In-DTPA0]octreotide (a stabilized radiolabeled somatostatin (SS) analogue, OctreoScan®) is widely used for the visualization and staging of somatostatin receptor-positive tumors. The application of likewise somatostatin analogues as vehicle for the deliverance of radionuclides to somatostatin receptor-positive targets are now in use for peptide receptor-targeted radionuclide therapy (PRRT). Currently preclinical and clinical investigation are ongoing trying to find the optimal combination of radionuclide and ligand. The anti-tumoral effects of such combinations, like [90Y-DOTA°, Tyr3]octreotide and [177Lu-DOTA°, Tyr3]-octreotate, on SSR-positive solid tumors have been reported. In this study we present the anti-tumor effects of 177Lu-DOTA-tate on: a) a single SSR-positive cell model and b) on a SSR-positive tumor in a rat liver micrometastatic model, mimicking disseminated disease. 177Lu-DOTA-tate showed anti-tumoral effects in both cases and significant survival in the PRRT-treated rats. 177Lu-DOTA-tate is a very promising new treatment modality for SSR-positive tumors, including disseminated disease.

, , , ,
doi.org/10.1002/ijc.10952, hdl.handle.net/1765/70236
International Journal of Cancer
Department of Surgery

Breeman, W., Mearadji, A., Capello, A., Bernard, B., van Euck, C., Krenning, E., & de Jong, M. (2003). Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model. International Journal of Cancer, 104(3), 376–379. doi:10.1002/ijc.10952